Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA Roundup: October 6, 2023Press Announcements FDA News Release
  FDA Roundup: October 6, 2023

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  October 06, 2023
 

  
      
       

  Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

Today, the FDA updated its infant formula compliance program for FDA investigators, laboratory analysts, and compliance officers. The compliance program is designed to comprehensively outline the agency’s approach for inspections, sample collection, sample analysis, and compliance activities to help ensure that infant formula products in the U.S. food supply are safe and nutritious. This effort is part of the FDA’s ongoing commitment to strengthen the safety, resiliency, and oversight of the infant formula industry.
	On Thursday, the FDA provided an update on the recalled Philips ventilators, BiPAP machines, and CPAP machines associated with the breakdown of PE-PUR foam. The FDA remains steadfast in our commitment that patients impacted by the recall deserve relief. While this matter is ongoing, the agency continues to monitor the company's recall progress and share new information with device users, patient care facilities, and other stakeholders. The FDA remains unsatisfied with the status of this recall, and we continue to take steps to protect the health and safety of individuals using these devices.
	As part of our continued efforts to ensure consumers have the latest information on the Philips recall, the FDA published a new resource section on FDA.gov, including a comprehensive timeline of FDA activities related to the June 2021 recall. Patients, consumers, and health care providers have played an integral part in providing feedback to the FDA about the Philips' recall, and their feedback is reflected in this new resource to ensure it provides timely and accurate information.
	On Wednesday, the FDA authorized marketing of the Marizyme, Inc.’s DuraGraft Vascular Conduit Solution, which is intended for flushing and short-term storage of saphenous vein grafts (either of the two chiefly superficial veins of the leg) from harvesting through grafting for adult patients undergoing coronary artery bypass grafting surgeries. The DuraGraft device is the first solution that is specifically labeled for this use.
	On Tuesday, the FDA announced the signing of a partnership agreement with the Pennsylvania Department of Agriculture’s Bureau of Food Safety & Laboratory Services that will focus on inventory reconciliation, reducing foodborne illness risk, and minimizing duplication of work. Through such partnerships, FDA works with states with comparable regulatory public health systems, as trusted partners, to rely on, coordinate with, and leverage one another’s work, data, and actions to meet the public health goal of a safe national food supply.
	The FDA's Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance program is hosting its 2023 NanoDay Symposium: Continuous Manufacturing of Nanomaterials on October 11. The symposium is open to the public and will provide an overview of CDER experience with approving several solid oral drug products which benefited from the continuous manufacturing technologies. The symposium will also feature case-studies of intramural and extramural research in the areas of nanomaterials and continuous manufacturing, to further encourage the innovation and adoption of continuous manufacturing. Register online.Related Information
  
  Related Information
              FDA Newsroom

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            FDA Office of Media Affairs
           
           
                      888-INFO-FDA
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      10/06/2023
               
               
Regulated Product(s)
		 Drugs
			  			     			  			     Food & Beverages
			     			  			     Medical Devices   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop